Oculis is a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet needs. Oculis’ late-stage pipeline includes OCS-01, a topical eye drop for DME; Privosegtor, a neuroprotective candidate for optic neuritis and NAION; and Licaminlimab, a topical anti-TNFα for DED. Headquartered in Switzerland, Oculis is led by an experienced management team and is supported by leading healthcare investors.